Showing results (61-70 of 174) with videos related to

Sort By:
Pageof 18
American Journal of Physiology. Endocrinology and Metabolism|December 7, 2017
Increased body fat mass explains the positive association between circulating estradiol and insulin resistance in postmenopausal womenGeneviève B Marchand, Anne-Marie Carreau, S John Weisnagel, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|May 18, 2006
Associations between hypertriglyceridemia, dietary fat intake, oxidative stress, and endothelial activation in menCharles Couillard, Sonia Pomerleau, Guillaume Ruel, et al.
Metabolism: Clinical and Experimental|July 17, 2009
Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrationsCaroline Payette, Patricia Blackburn, Benoît Lamarche, et al.
Atherosclerosis|August 17, 2014
PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification programBenoit J Arsenault, Emilie Pelletier-Beaumont, Natalie Alméras, et al.
Journal of Clinical Apheresis|May 27, 2015
Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemiaJean-Philippe Drouin-Chartier, André J Tremblay, Jean Bergeron, et al.
Metabolism: Clinical and Experimental|November 19, 2003
Influences of apolipoprotein E polymorphism on the response of plasma lipids to the ad libitum consumption of a high-carbohydrate diet compared with a high-monounsaturated fatty acid dietPatrick Couture, W Roodly Archer, Benoît Lamarche, et al.
Lancet (London, England)|May 29, 2012
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trialEvan A Stein, Dan Gipe, Jean Bergeron, et al.
Reviews in Cardiovascular Medicine|November 1, 2024
Erratum: Leiter <i>et al</i>. Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Reviews in Cardiovascular Medicine. 2024; 25: 190Lawrence A Leiter, Robert A Hegele, Vivien Brown, et al.
Reviews in Cardiovascular Medicine|July 30, 2024
Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular DiseaseLawrence A Leiter, Robert A Hegele, Vivien Brown, et al.
The American Journal of Clinical Nutrition|July 30, 2002
Evidence for impaired lipolysis in abdominally obese men: postprandial study of apolipoprotein B-48- and B-100-containing lipoproteinsCharles Couillard, Nathalie Bergeron, Agnès Pascot, et al.
Pageof 18